Literature DB >> 20452372

Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China.

Xiaomao Yin1, Zhaoxian Yu.   

Abstract

OBJECTIVE: Fluoroquinolone (FQ)-resistant Mycobacterium tuberculosis (MTB) clinical isolates have emerged in many areas of the world. The aim of this study was to observe the molecular characterization of gyrA and gyrB genes in FQ-resistant MTB clinical isolates from Guangdong Province in China.
MATERIALS AND METHODS: A total of 62 MTB clinical strains were originally isolated from patients with pulmonary tuberculosis. The phenotype of susceptibility of each strain was determined by the absolute concentration method and the sequences of the QRDR in gyrA and gyrB genes were detected with DNA direct sequencing technique.
RESULTS: 44 of 60 (73.3%) levofloxacin-resistant MTB clinical isolates, including 17 of 18 (94.4%) high-level resistant strains and 27 of 42 (64.3%) low-level resistant strains, had mutation in QRDR of gyrA gene. The mutation patterns involved six patterns of single codon mutation (H70R, A90V, S91A, D94G, D94A or D94N) and one pattern of double codons mutation (A90V with D94A). Of 60 levofloxacin-resistant MTB clinical isolates, only one (1.6%) mutated in gyrB gene (T511N).
CONCLUSIONS: These findings confirm that mutations of gyrA codons 90, 91 and 94 constitute the primary mechanism of FQ resistance in MTB. Furthermore, our findings indicate that the regional investigations are necessary for the comprehensive understanding of FQ resistance of MTB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452372     DOI: 10.1016/j.jinf.2010.05.001

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  22 in total

Review 1.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

Review 2.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 3.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

4.  Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.

Authors:  Delia Blanco; Esther Perez-Herran; Mónica Cacho; Lluís Ballell; Julia Castro; Rubén González Del Río; José Luis Lavandera; Modesto J Remuiñán; Cindy Richards; Joaquin Rullas; María Jesús Vázquez-Muñiz; Ermias Woldu; María Cleofé Zapatero-González; Iñigo Angulo-Barturen; Alfonso Mendoza; David Barros
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

5.  Amino acid substitutions at position 95 in GyrA can add fluoroquinolone resistance to Mycobacterium leprae.

Authors:  Kazumasa Yokoyama; Hyun Kim; Tetsu Mukai; Masanori Matsuoka; Chie Nakajima; Yasuhiko Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

6.  Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Nicolas Veziris; Florence Brossier; Sylvaine Bastian; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

7.  Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.

Authors:  Jung-Yien Chien; Wei-Yih Chiu; Shun-Tien Chien; Chia-Jung Chiang; Chong-Jen Yu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

8.  Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China.

Authors:  Xiaoliang Yuan; Tiantuo Zhang; Kazuyoshi Kawakami; Jiaxin Zhu; Hongtao Li; Jianping Lei; Shaohua Tu
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

9.  Genetic and phenotypic characterizations of drug-resistant Mycobacterium tuberculosis isolates in Cheonan, Korea.

Authors:  Jae-Sik Jeon; Jae Kyung Kim; Qute Choi; Jong Wan Kim
Journal:  J Clin Lab Anal       Date:  2018-02-03       Impact factor: 2.352

10.  Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.

Authors:  Pooja Singh; Amita Jain; Pratima Dixit; Shantanu Prakash; Indu Jaiswal; Vimala Venkatesh; Mastan Singh
Journal:  J Antibiot (Tokyo)       Date:  2014-07-23       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.